Health Trials

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.

Participants needed: 92
Trial details
Phase: Phase 2Age: 3-10Biological sex: AllType: InterventionalSponsor: Tyra Biosciences, IncUpdated: Jul 13, 2026Locations: 19
Eligibility criteria

Aged 3 to 10 years old (inclusive) at the time of consent. [+8]

Presence or history of any concurrent disease or condition that would interfere... [+5]

Read more
Status: Recruiting

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma

Participants needed: 230
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Tyra Biosciences, IncUpdated: Jul 2, 2026Locations: 12
Eligibility criteria

Participants ≥ 18 years of age at the time of informed consent and willing and a... [+15]

Evidence or any features of high grade (HG) UTUC [+13]

Read more
Status: Recruiting

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.

Participants needed: 92
Trial details
Phase: Phase 2Age: 3-10Biological sex: AllType: InterventionalSponsor: Tyra Biosciences, IncUpdated: Jun 30, 2026Locations: 18
Eligibility criteria

Aged 3 to 10 years old (inclusive) at the time of consent. [+8]

Presence or history of any concurrent disease or condition that would interfere... [+5]

Read more
Status: Recruiting

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

Participants needed: 90
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Tyra Biosciences, IncUpdated: Jun 29, 2026Locations: 45
Eligibility criteria

Participants age 18 and over of informed consent and willing and able to comply... [+21]

Current or previous history of muscle invasive bladder cancer [+24]

Read more
Status: Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

Participants needed: 100
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Tyra Biosciences, IncUpdated: Nov 20, 2025Locations: 16
Eligibility criteria

Age ≥ 18 years [+18]

Have disease that is suitable for local therapy administered with curative inten... [+16]

Read more
Status: Recruiting

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.

Participants needed: 40
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Tyra Biosciences, IncUpdated: Oct 3, 2024Locations: 4
Eligibility criteria

Men and women 18 years of age or older. [+9]

Discontinued a prior anti-FGFR therapy due to significant toxicity, defined as h... [+6]

Read more